Welcome to our dedicated page for Vtv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on Vtv Therapeutics stock.
vTv Therapeutics Inc. (Nasdaq: VTVT) is a late-stage biopharmaceutical company focused on oral, small molecule drug candidates for diabetes and other chronic diseases. News about VTVT frequently centers on the development of its lead program, cadisegliatin (TTP399), a novel liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment to insulin for people with type 1 diabetes.
Company updates often cover key milestones in the CATT1 Phase 3 trial of cadisegliatin in adults with type 1 diabetes, including trial initiation, randomization of the first study participant, and expectations for topline data. vTv Therapeutics also issues news on its Phase 2 clinical study protocol for cadisegliatin as an adjunctive therapy to insulin in people with type 2 diabetes, developed in collaboration with M42’s Insights Research Organization & Solutions (IROS) for sites in the United Arab Emirates, Jordan, and Tunisia.
Investors following VTVT news can expect regular clinical development updates, such as preclinical and clinical data presentations at scientific meetings, including the INNODIA Symposium at the European Association for the Study of Diabetes Annual Meeting. The company also reports on intellectual property developments, including U.S. patent allowances for crystalline forms of cadisegliatin with patent terms running through 2041.
Another recurring theme in vTv Therapeutics news is financing and corporate activity, such as private placements with healthcare institutional investors and the T1D Fund intended to support the CATT1 Phase 3 trial and broader cadisegliatin program. Updates on participation in investor conferences and changes to scientific advisory structures also appear in the news flow.
For readers tracking VTVT stock, this news page aggregates company press releases and related coverage so they can monitor progress in clinical trials, regulatory interactions, patent protection, and capital-raising efforts tied to vTv Therapeutics’ diabetes-focused pipeline.
vTv Therapeutics (Nasdaq: VTVT) has entered into a $10 million investment agreement with CinPax, a subsidiary of CinRx Pharma. Under this deal, CinPax acquires over 4 million shares at approximately $2.41 each, with $6 million paid upfront and $4 million due by November 22, 2022. This investment will support vTv's Phase 3 clinical trials for TTP399, a glucokinase activator for type 1 diabetes. CinRx will leverage its expertise to assist in clinical trial oversight. vTv recently secured an additional $25 million from G42 Healthcare for the same purpose.
vTv Therapeutics (Nasdaq: VTVT) announced promising results of TTP399, a glucokinase activator for type 1 diabetes (T1D), showing it improves glycemia without increasing hypoglycemia risk. Findings from a JDRF-supported study indicated no cases of diabetic ketoacidosis (DKA) in TTP399-treated participants, while 42% of placebo subjects met DKA criteria. The study, published in Diabetes Obesity and Metabolism and presented at the ADA 2022 conference, supports TTP399's potential as a safe adjunct therapy for T1D.
On June 1, 2022, vTv Therapeutics (Nasdaq: VTVT) announced a $25 million investment from G42 Investments, acquiring 10,386,274 shares at $2.407 each. The investment partly funds Phase 3 clinical trials for TTP399, a glucokinase activator for type 1 diabetes. Additional shares worth $30 million may be issued if the FDA approves TTP399. This collaboration signifies a strategic partnership aimed at accelerating drug development and commercialization, leveraging G42's resources and expertise. TTP399 has shown promising results, including significant reductions in hypoglycemic episodes.
vTv Therapeutics Inc. (Nasdaq: VTVT) reported Q1 2022 financial results, highlighting a revenue of $2 million, primarily due to increased transaction prices from licensing agreements. The company continues to focus on its lead program TTP399 for type 1 diabetes while pausing development on HPP737. As of March 31, 2022, cash reserves were $12.1 million. Net loss before non-controlling interest was $9.4 million, slightly down from $9.5 million in the previous quarter. The diluted net loss per share improved to ($0.10).
vTv Therapeutics Inc. (Nasdaq: VTVT) reported its financial results for Q4 and the full year ended December 31, 2021. The company experienced a net loss of $9.5 million for Q4, increasing from $1.5 million in Q3 2021. Revenue for Q4 was negligible at $9 compared to $3 million in Q3. R&D expenses rose to $5.4 million, while G&A expenses surged to $5.7 million. The company has appointed Richard Nelson as Acting CEO and is focusing on developing TTP399 for type 1 diabetes, with plans for pivotal trials commencing in Q3 2022. Cash decreased to $13.4 million by year-end.
vTv Therapeutics Inc. (Nasdaq: VTVT) announced the appointment of Rich Nelson as Acting CEO following the resignation of Deepa Prasad. Nelson, a board member since 2020, brings extensive experience in corporate development and mergers. Prasad will remain as a Strategic Advisor for six months. The company is focused on advancing its lead drug, TTP399, which received FDA Breakthrough Therapy Designation after showing a 40% reduction in hypoglycemic episodes in its Phase 2 study. vTv aims to launch pivotal trials for TTP399 in 2022.
vTv Therapeutics (Nasdaq: VTVT) has updated its corporate presentation on TTP399, a novel treatment aimed at reducing hypoglycemic episodes in diabetes patients. The drug may act as an oral adjunctive therapy in the $16B insulin market. Nearly 600 patients have been tested with no diabetic ketoacidosis reported. vTv holds worldwide rights for TTP399 and plans global pivotal trials in 2022 while seeking non-dilutive capital through licensing outside North America and Europe. Additionally, the company explores licensing for HPP737 and other assets.
vTv Therapeutics Inc. (Nasdaq: VTVT) announced a 65% workforce reduction to prioritize its lead program, TTP399, for type 1 diabetes, as it prepares for Phase 3 pivotal trials. TTP399 demonstrated a ~40% reduction in hypoglycemic episodes compared to placebo in Phase 2 studies and has received Breakthrough Therapy Designation from the FDA. The company also suspended development on HPP737, a psoriasis treatment, while supporting partnered programs. vTv aims to focus on improving the quality of life for diabetes patients with TTP399.
vTv Therapeutics Inc. (Nasdaq: VTVT) reported third-quarter 2021 financial results, highlighting a cash position of $19.6 million, up from $10.8 million in Q2 2021. The company generated $3.0 million in revenue, largely from milestones achieved with partners. Net loss attributable to shareholders was $1.09 million, or $(0.02) per share, compared to $(0.01) in Q2 2021. The firm is refocusing on TTP399 for type 1 diabetes, having received FDA Breakthrough Therapy Designation. Upcoming pivotal studies for TTP399 are planned for H1 2022, with cost reduction measures being evaluated.
vTv Therapeutics Inc. (Nasdaq: VTVT) announces the appointment of Deepa Prasad as President and CEO, effective immediately, following the retirement of Stephen L. Holcombe. Under her leadership, the company plans to launch phase 3 studies for TTP399, an oral therapy for type 1 diabetes, which received Breakthrough Therapy Designation from the FDA. Recent phase 2 results showed significant HbA1c improvement and reduced hypoglycemia risk. Prasad brings over 20 years of healthcare experience, having previously led investments in prominent firms.